As Singapore embarks on system-wide changes in healthcare delivery, public and private actors see a window of opportunity to increase the understanding of value-based care delivery and financing models that link reimbursement to population health outcomes. At this symposium, speakers will provide global perspectives for advancing high-value health care, touching on cost sustainability, financing models to support innovation, and lessons that Singapore can incorporate into the local health system. Key stakeholders from the health ministry, healthcare clusters, and academia will share current efforts, opportunities and challenges in implementation of innovative healthcare financing models in Singapore.
Adapting patient care to an environment of evolving medical knowledge and innovative product development demands a sharp ability to forecast the upcoming needs of the future. Regulatory systems are expected to support innovation and facilitate patients’ access to new effective treatments.
The increasing involvement of patients in shaping health policies and decision-making indicates the progressive movement towards patient-centric care. In light of these trends, various stakeholders are responding to the changing environment and adapting to accommodate new demands.
Hear from the speakers, as they share from their experiences and present global perspectives in envisioning optimal approaches for advancing public health.
Thank you for your interest in our Graduate Certificate Programme. Please click below to sign up for GMS5104:Biotherapeutics and Biosimilars Course.
THANK YOU FOR YOUR OVERWHELMING SUPPORT.
REGISTRATION IS NOW CLOSED.
Expert pharmacovigilance trainers from the World Health Organisation (WHO), the Uppsala Monitoring Centre (UMC), and the Health Sciences Authority (HSA) of Singapore, will share with participants their expertise and experience over a 3-day workshop, jointly organised with the WHO, UMC, HSA, and CoRE, as part of a continuation of efforts to enhance pharmacovigilance capabilities in the ASEAN region. Given this year’s underlying theme of “Partnerships to Protect Public Health”, we welcome participation from non-regulators, such as people from the industry and non-government organisations (NGOs).
THANK YOU FOR YOUR OVERWHELMING SUPPORT.
REGISTRATION IS NOW CLOSED.
Advanced Therapies is a rapidly advancing field that offers exciting new therapeutic possibilities. To promote a better understanding of the frameworks and processes regulating cell, tissue, and gene therapies, this 2.5-day workshop provides a platform for global and regional experts to share their expertise and experience, including major and regional regulatory authorities, as well as leading companies in this domain. This second pilot workshop has been co-developed with guidance from APEC Life Sciences Innovation Forum Regulatory Harmonization Steering Committee (RHSC) and a programme committee consisting of the Health Sciences Authority (HSA) Singapore, and key opinion leaders from industry and scientific organisations.
Following up on CoRE’s previous Seminar Series on regulatory developments in China, China's regulatory agency has since met all of its objectives to initiate reforms to its regulatory frameworks in 2017. This resulted in a reduction of lag time, increase in regulatory capacity and the implementation of a science-based regulatory review approach. To further improve China’s regulatory environment, the Deepening Reform was implemented in October 2017 which has resulted in the publication of various new guidelines, regulations and requirements. In light of these rapid and successive changes, this seminar examines the key reforms and their impact on the global regulatory environment in the near future.
Accessibility to accurate and reliable information is essential to healthcare professionals and patients for ensuring the safe and correct use of health products. A trend of providing electronic product information, or e-labelling, over the use of traditional printed labels is accelerating. This shift in improving accessibility to information opens up exciting possibilities for health literacy, but also raises concerns. The advent of the internet and social media has resulted in an explosion of alternative information sources, increasing the risk of accessing incorrect information, and potentially compromising the appropriate use of health products. CoRE welcomes you to join us for this seminar with Dr Shimon Yoshida on the potential for e-labelling in Asia and sharing initiatives from other parts of the world. Closing the seminar will be a panel discussion with representatives from the healthcare sector, regulatory authority and industry to further discuss the contemporary topic of e-labelling.
We are pleased to welcome you to the launch of the Duke-NUS Centre of Regulatory Excellence (CoRE) Graduate Certificate in Pharmaceutical Regulation. This is dedicated regulatory training programme caters to the learning needs of regulatory professionals in national regulatory authorities and industry, researchers, healthcare professionals and other stakeholders interested to gain a deeper understanding of regulatory science, both in terms of international best practice and specific relevance to South-East Asia and Asia-Pacific. To find out more, join us at the open house.
Singapore’s rapidly ageing population and growing burden of chronic diseases have created a new imperative for population health improvement. These challenges open new opportunities for policymakers and providers to source and scale payment and delivery innovations to fill key needs. For example, initiatives such as the new Health IT Master Plan (HITMAP) highlight how the path towards population health will depend on the capacity to collect, share, analyse, and act upon health and social data. This talk will provide a global perspective on policy, payment, and delivery innovations that hold promise to improve health and healthcare, and opportunities in Singapore to incorporate global lessons to transform the health system toward population health.
Data sources such as electronic health records and patient registries enable the development of real world evidence (RWE), which can inform decisions across the medical product lifecycle, including treatment decisions and those that impact care quality as well as payment and delivery. While the U.S. FDA has relied on RWE to support decision-making in specific contexts, there are further opportunities for RWE to further enhance the regulatory framework, especially regarding efficacy and benefit. CoRE invites you to join us for Professor Gregory Daniel’s seminar, which will: 1) provide an update on the current U.S. policy landscape with respect to RWE; 2) describe current efforts to support the enhanced development and use of RWE across a range of activities; and 3) stimulate discussion on how lessons from the U.S. context might inform existing efforts in Singapore.